Zura Bio

NAQ:ZURA · KYG9TY5A1016

BiotechnologySmall

360° View

Value46

Price/Sales—

Price/Earnings56

Price/Book58

Dividend Yield1

Growth90

Revenue Growth—

Profit Growth53

Capital Growth87

TSR 52w79

Safety38

Leverage92

Liquidity25

Refinancing29

Combined62

Sentiment57

Analyst Opinions74

Pro Holdings45

Opinion Changes50

Market Pulse53

Profile

CountryUSA

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQCM

Employees49

Websitezurabio.com

ISINKYG9TY5A1016

Last UpdateApr 2, 2026

Index & Theme

RheumatologyChronic DiseasesImmunologyInflammationBiopharmaBiotechnologyLife ScienceMedical

Description

Zura Bio Limited operates as a clinical-stage, multi-asset immunology company dedicated to developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases with unmet needs. Leveraging the extensive experience of the comp…

Analysis

Zura Bio's 360° View rank of 56 places it above its peer average — better than 56% of its true peers.

It's a growth standout (90) and on the expensive side (46). On safety it is carrying more balance-sheet risk (38), and the market shows favorable sentiment (57). Taken together, its Combined rank of 62 reads as above its peer average.

360° rank · history

1007550250

2026

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Zura Bio with its peers

Oruka Therapeutics

NMQ:ORKA

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Shattuck Labs

NSQ:STTK

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Tharimmune

NAQ:THAR

—

CountryUSA

IndustryBiotechnology

SizeX-Small

Full Stock Analysis →

Pyxis Oncology

NSQ:PYXS

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Zenas Biopharma

NSQ:ZBIO

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Kymera Therapeutics

NMQ:KYMR

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →